Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder

NCT00191295 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder
Lead sponsor
Eli Lilly and Company
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 2005
Completion date
September 30, 2006
Enrollment
240
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder